Nektar TherapeuticsNKTRNASDAQ
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
5.50%
↓ 94% below average
Average (39q)
91.03%
Historical baseline
Range
High:3349.56%
Low:-97.88%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 5.50% |
| Q2 2025 | 6.84% |
| Q1 2025 | -50.66% |
| Q4 2024 | 7.66% |
| Q3 2024 | 43.20% |
| Q2 2024 | 4.91% |
| Q1 2024 | -21.06% |
| Q4 2023 | 41.74% |
| Q3 2023 | -13.27% |
| Q2 2023 | -7.08% |
| Q1 2023 | -7.95% |
| Q4 2022 | -15.35% |
| Q3 2022 | 13.25% |
| Q2 2022 | -15.57% |
| Q1 2022 | 3.51% |
| Q4 2021 | -3.90% |
| Q3 2021 | -5.10% |
| Q2 2021 | 15.49% |
| Q1 2021 | -6.52% |
| Q4 2020 | -21.76% |
| Q3 2020 | -43.21% |
| Q2 2020 | -7.89% |
| Q1 2020 | 67.77% |
| Q4 2019 | 14.75% |
| Q3 2019 | 32.76% |
| Q2 2019 | -19.69% |
| Q1 2019 | -29.61% |
| Q4 2018 | 40.85% |
| Q3 2018 | -97.88% |
| Q2 2018 | 3349.56% |
| Q1 2018 | -63.40% |
| Q4 2017 | -41.79% |
| Q3 2017 | 475.21% |
| Q2 2017 | 37.66% |
| Q1 2017 | -39.71% |
| Q4 2016 | 5.27% |
| Q3 2016 | 16.93% |
| Q2 2016 | -49.89% |
| Q1 2016 | 61.30% |
| Q4 2015 | -41.71% |